Erasca, Inc. (NASDAQ: ERAS) Stock Competitors & Peer Comparison

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while VRTX trades at $477.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas VRTX's P/E ratio is 25.35. In terms of profitability, ERAS's ROE is -0.77%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ERAS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check VRTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while REGN trades at $762.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas REGN's P/E ratio is 16.71. In terms of profitability, ERAS's ROE is -0.77%, compared to REGN's ROE of +0.18%. Regarding short-term risk, ERAS is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check REGN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ERAS's ROE is -0.77%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ERAS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check VRNA's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ARGX trades at $853.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ARGX's P/E ratio is 78.75. In terms of profitability, ERAS's ROE is -0.77%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ERAS is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ARGX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ERAS's ROE is -0.77%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ERAS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check SGEN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RVMDW trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, ERAS's ROE is -0.77%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ERAS is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check RVMDW's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RVMD trades at $187.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RVMD's P/E ratio is -26.52. In terms of profitability, ERAS's ROE is -0.77%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ERAS is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check RVMD's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ONC trades at $316.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ONC's P/E ratio is 70.70. In terms of profitability, ERAS's ROE is -0.77%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ERAS is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ONC's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ALNY trades at $205.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ALNY's P/E ratio is 37.02. In terms of profitability, ERAS's ROE is -0.77%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ERAS is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ALNY's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ROIV trades at $33.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ROIV's P/E ratio is -34.86. In terms of profitability, ERAS's ROE is -0.77%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ERAS is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ROIV's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while INCY trades at $119.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas INCY's P/E ratio is 16.06. In terms of profitability, ERAS's ROE is -0.77%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ERAS is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check INCY's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while BNTX trades at $90.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas BNTX's P/E ratio is -19.61. In terms of profitability, ERAS's ROE is -0.77%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ERAS is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check BNTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while UTHR trades at $517.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas UTHR's P/E ratio is 19.10. In terms of profitability, ERAS's ROE is -0.77%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ERAS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check UTHR's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while MRNA trades at $54.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas MRNA's P/E ratio is -6.73. In terms of profitability, ERAS's ROE is -0.77%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ERAS is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check MRNA's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while INSM trades at $98.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas INSM's P/E ratio is -17.15. In terms of profitability, ERAS's ROE is -0.77%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ERAS is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check INSM's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ERAS's ROE is -0.77%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ERAS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check BGNE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ERAS's ROE is -0.77%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ERAS is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check DNA-WT's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while GMAB trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas GMAB's P/E ratio is 20.77. In terms of profitability, ERAS's ROE is -0.77%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ERAS is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check GMAB's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while NBIX trades at $166.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas NBIX's P/E ratio is 24.10. In terms of profitability, ERAS's ROE is -0.77%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ERAS is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check NBIX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while JAZZ trades at $252.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, ERAS's ROE is -0.77%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ERAS is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check JAZZ's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while BBIO trades at $80.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas BBIO's P/E ratio is -21.41. In terms of profitability, ERAS's ROE is -0.77%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ERAS is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check BBIO's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ASND trades at $243.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ASND's P/E ratio is -100.79. In terms of profitability, ERAS's ROE is -0.77%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ERAS is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ASND's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while EXEL trades at $53.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas EXEL's P/E ratio is 15.88. In terms of profitability, ERAS's ROE is -0.77%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ERAS is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check EXEL's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ERAS's ROE is -0.77%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ERAS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check KRTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ARWR trades at $84.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ARWR's P/E ratio is -39.37. In terms of profitability, ERAS's ROE is -0.77%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ERAS is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ARWR's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while BMRN trades at $60.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas BMRN's P/E ratio is 28.86. In terms of profitability, ERAS's ROE is -0.77%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ERAS is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check BMRN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while TECH trades at $72.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas TECH's P/E ratio is 37.16. In terms of profitability, ERAS's ROE is -0.77%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ERAS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check TECH's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ERAS's ROE is -0.77%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ERAS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check RNAM's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while AXSM trades at $217.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas AXSM's P/E ratio is -56.92. In terms of profitability, ERAS's ROE is -0.77%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ERAS is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check AXSM's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while MDGL trades at $467.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas MDGL's P/E ratio is -36.51. In terms of profitability, ERAS's ROE is -0.77%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ERAS is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check MDGL's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while SMMT trades at $13.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas SMMT's P/E ratio is -8.14. In terms of profitability, ERAS's ROE is -0.77%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ERAS is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check SMMT's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while KRYS trades at $341.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas KRYS's P/E ratio is 45.60. In terms of profitability, ERAS's ROE is -0.77%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ERAS is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check KRYS's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while HALO trades at $82.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas HALO's P/E ratio is 17.87. In terms of profitability, ERAS's ROE is -0.77%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ERAS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check HALO's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CYTK trades at $77.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CYTK's P/E ratio is -13.23. In terms of profitability, ERAS's ROE is -0.77%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ERAS is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CYTK's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ERAS's ROE is -0.77%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check RXDX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ABVX trades at $124.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ABVX's P/E ratio is -65.48. In terms of profitability, ERAS's ROE is -0.77%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ERAS is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ABVX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ERAS's ROE is -0.77%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ERAS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check NUVL's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CRNX trades at $83.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CRNX's P/E ratio is -16.28. In terms of profitability, ERAS's ROE is -0.77%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ERAS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CRNX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while PTGX trades at $136.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas PTGX's P/E ratio is -75.49. In terms of profitability, ERAS's ROE is -0.77%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ERAS is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check PTGX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ERAS's ROE is -0.77%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ERAS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check IMGN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while IONS trades at $51.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas IONS's P/E ratio is -30.10. In terms of profitability, ERAS's ROE is -0.77%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ERAS is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check IONS's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while PRAX trades at $307.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas PRAX's P/E ratio is -23.02. In terms of profitability, ERAS's ROE is -0.77%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ERAS is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check PRAX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while SYRE trades at $98.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas SYRE's P/E ratio is -47.27. In terms of profitability, ERAS's ROE is -0.77%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check SYRE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while KYMR trades at $103.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas KYMR's P/E ratio is -29.29. In terms of profitability, ERAS's ROE is -0.77%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ERAS is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check KYMR's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ALKS trades at $48.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ALKS's P/E ratio is 52.66. In terms of profitability, ERAS's ROE is -0.77%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ERAS is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ALKS's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ERAS's ROE is -0.77%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check BPMC's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while APGE trades at $134.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas APGE's P/E ratio is -30.97. In terms of profitability, ERAS's ROE is -0.77%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check APGE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CERE's P/E ratio is -16.47. In terms of profitability, ERAS's ROE is -0.77%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ERAS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CERE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while TGTX trades at $52.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas TGTX's P/E ratio is 17.88. In terms of profitability, ERAS's ROE is -0.77%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ERAS is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check TGTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while IMVT trades at $38.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas IMVT's P/E ratio is -14.46. In terms of profitability, ERAS's ROE is -0.77%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ERAS is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check IMVT's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while PCVX trades at $54.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas PCVX's P/E ratio is -7.86. In terms of profitability, ERAS's ROE is -0.77%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ERAS is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check PCVX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while IBRX trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas IBRX's P/E ratio is -8.44. In terms of profitability, ERAS's ROE is -0.77%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ERAS is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check IBRX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ERAS's ROE is -0.77%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ERAS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check MTSR's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ERAS's ROE is -0.77%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ERAS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check MRUS's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RYTM trades at $99.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RYTM's P/E ratio is -31.71. In terms of profitability, ERAS's ROE is -0.77%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ERAS is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check RYTM's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ERAS's ROE is -0.77%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ERAS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ACLX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while COGT trades at $38.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas COGT's P/E ratio is -18.45. In terms of profitability, ERAS's ROE is -0.77%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ERAS is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check COGT's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RETA's P/E ratio is -66.29. In terms of profitability, ERAS's ROE is -0.77%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ERAS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check RETA's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while MIRM trades at $105.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas MIRM's P/E ratio is -7.78. In terms of profitability, ERAS's ROE is -0.77%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ERAS is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check MIRM's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while BLTE trades at $158.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas BLTE's P/E ratio is -84.82. In terms of profitability, ERAS's ROE is -0.77%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ERAS is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check BLTE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CGON trades at $71.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CGON's P/E ratio is -30.55. In terms of profitability, ERAS's ROE is -0.77%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ERAS is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CGON's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ERAS's ROE is -0.77%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ERAS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CNTA's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while XENE trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas XENE's P/E ratio is -13.33. In terms of profitability, ERAS's ROE is -0.77%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ERAS is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check XENE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while LGND trades at $287.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas LGND's P/E ratio is 34.48. In terms of profitability, ERAS's ROE is -0.77%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ERAS is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check LGND's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while SRRK trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas SRRK's P/E ratio is -13.17. In terms of profitability, ERAS's ROE is -0.77%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ERAS is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check SRRK's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while PTCT trades at $68.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas PTCT's P/E ratio is -29.19. In terms of profitability, ERAS's ROE is -0.77%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ERAS is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check PTCT's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ERAS's ROE is -0.77%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ERAS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CDTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ERAS's ROE is -0.77%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ERAS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ABCM's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ERAS's ROE is -0.77%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ERAS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ISEE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas APLS's P/E ratio is 38.35. In terms of profitability, ERAS's ROE is -0.77%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ERAS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check APLS's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while TVTX trades at $55.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas TVTX's P/E ratio is -254.05. In terms of profitability, ERAS's ROE is -0.77%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ERAS is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check TVTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas TERN's P/E ratio is -51.41. In terms of profitability, ERAS's ROE is -0.77%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ERAS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check TERN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while DFTX trades at $43.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas DFTX's P/E ratio is N/A. In terms of profitability, ERAS's ROE is -0.77%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ERAS is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check DFTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while DYN trades at $25.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas DYN's P/E ratio is -7.82. In terms of profitability, ERAS's ROE is -0.77%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ERAS is similarly volatile compared to DYN. This indicates similar risk in terms of short-term price fluctuations for ERAS.Check DYN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CRSP trades at $47.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CRSP's P/E ratio is -9.39. In terms of profitability, ERAS's ROE is -0.77%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ERAS is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CRSP's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ERAS's ROE is -0.77%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ERAS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check FOLD's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ERAS's ROE is -0.77%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ERAS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check AKRO's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while DNTH trades at $106.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas DNTH's P/E ratio is -25.89. In terms of profitability, ERAS's ROE is -0.77%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ERAS is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check DNTH's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ERAS's ROE is -0.77%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ERAS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ALPN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ACAD trades at $25.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ACAD's P/E ratio is 12.68. In terms of profitability, ERAS's ROE is -0.77%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ERAS is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ACAD's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CAI trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CAI's P/E ratio is -86.19. In terms of profitability, ERAS's ROE is -0.77%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ERAS is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CAI's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while MANE trades at $105.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas MANE's P/E ratio is -33.36. In terms of profitability, ERAS's ROE is -0.77%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ERAS is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check MANE's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas OPT's P/E ratio is -1.52. In terms of profitability, ERAS's ROE is -0.77%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ERAS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check OPT's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ERAS's ROE is -0.77%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ERAS is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check PRTC's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CELC trades at $86.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CELC's P/E ratio is -22.15. In terms of profitability, ERAS's ROE is -0.77%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ERAS is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CELC's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while EWTX trades at $38.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas EWTX's P/E ratio is -23.15. In terms of profitability, ERAS's ROE is -0.77%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ERAS is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check EWTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ERAS's ROE is -0.77%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ERAS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check MRTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ELVN trades at $54.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ELVN's P/E ratio is -32.82. In terms of profitability, ERAS's ROE is -0.77%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ERAS is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ELVN's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ERAS's ROE is -0.77%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ERAS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CPRX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ERAS's ROE is -0.77%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ERAS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check RYZB's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ERAS's ROE is -0.77%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ERAS is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check CBAY's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while VKTX trades at $31.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas VKTX's P/E ratio is -7.67. In terms of profitability, ERAS's ROE is -0.77%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ERAS is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check VKTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while DNLI trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas DNLI's P/E ratio is -7.99. In terms of profitability, ERAS's ROE is -0.77%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ERAS is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check DNLI's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ORKA trades at $96.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ORKA's P/E ratio is -49.75. In terms of profitability, ERAS's ROE is -0.77%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, ERAS is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check ORKA's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ADPT trades at $22.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ADPT's P/E ratio is -41.80. In terms of profitability, ERAS's ROE is -0.77%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, ERAS is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ERAS.Check ADPT's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ALMS trades at $28.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ALMS's P/E ratio is -7.39. In terms of profitability, ERAS's ROE is -0.77%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, ERAS is more volatile compared to ALMS. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ALMS's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while RCUS trades at $28.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas RCUS's P/E ratio is -8.66. In terms of profitability, ERAS's ROE is -0.77%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, ERAS is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check RCUS's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ERAS's ROE is -0.77%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ERAS is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check SWTX's competition here

Erasca, Inc. (NASDAQ: ERAS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERAS stands at 6.3B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, ERAS is priced at $18.15 on the NASDAQ, while ARQT trades at $26.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERAS currently has a P/E ratio of -19.51, whereas ARQT's P/E ratio is -933.00. In terms of profitability, ERAS's ROE is -0.77%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, ERAS is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for ERAS.Check ARQT's competition here